This paper examines whether inhibitor kappa B kinase 2 (IKK2) acts as a myosin light chain kinase (MLCK) or regulates the activity of myosin light chain phosphatase (MLCP), and therefore affects vasoconstriction. The authors found that IKK2 regulates MLCP activity by phosphorylating the MYPT1 subunit. Furthermore, SC-514, an IKK2 inhibitor, induces relaxation of mesenteric arteries. Therefore, IKK2 may be a new pharmacological target for treatment of various vascular diseases.
- Youngin Kwon
- Soo-Kyoung Choi
- Young-Ho Lee